RCC患者-话题@MedSci

[GetTopicListResponse(id=1793163, encodeId=baf31e931630c, content=<a href='/topic/show?id=515b1519009' target=_blank style='color:#2F92EE;'>#RCC患者#</a>, objectTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, objectType=article, longId=219447, objectId=234a21944e5a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234a21944e5a, replyNumber=0, likeNumber=47, createdTime=2021-11-04, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234a21944e5a, moduleTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234a21944e5a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793161, encodeId=22d61e9316123, content=<a href='/topic/show?id=515b1519009' target=_blank style='color:#2F92EE;'>#RCC患者#</a>, objectTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, objectType=article, longId=215476, objectId=dc262154e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc262154e628, replyNumber=0, likeNumber=30, createdTime=2022-03-25, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc262154e628, moduleTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc262154e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793162, encodeId=25641e93162a3, content=<a href='/topic/show?id=515b1519009' target=_blank style='color:#2F92EE;'>#RCC患者#</a>, objectTitle=Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果, objectType=article, longId=216261, objectId=ba64216261c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba64216261c5, replyNumber=0, likeNumber=39, createdTime=2022-07-20, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba64216261c5, moduleTitle=Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba64216261c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793164, encodeId=5a991e931645a, content=<a href='/topic/show?id=515b1519009' target=_blank style='color:#2F92EE;'>#RCC患者#</a>, objectTitle=JAMA子刊：掀起“谈痣色变”风的黑色素瘤与肾癌密不可分！46岁以下RCC患者都应该进行这些基因筛查！, objectType=article, longId=220370, objectId=c45f2203e030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c45f2203e030, replyNumber=0, likeNumber=44, createdTime=2022-09-26, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c45f2203e030, moduleTitle=JAMA子刊：掀起“谈痣色变”风的黑色素瘤与肾癌密不可分！46岁以下RCC患者都应该进行这些基因筛查！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c45f2203e030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793160, encodeId=7ff01e93160df, content=<a href='/topic/show?id=515b1519009' target=_blank style='color:#2F92EE;'>#RCC患者#</a>, objectTitle=Cell Death & Disease：抗雌激素药物Faslodex能够增加RCC患者对Sunitinib的敏感性, objectType=article, longId=195178, objectId=e7211951e8de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7211951e8de, replyNumber=0, likeNumber=36, createdTime=2021-04-26, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7211951e8de, moduleTitle=Cell Death & Disease：抗雌激素药物Faslodex能够增加RCC患者对Sunitinib的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7211951e8de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793159, encodeId=e78d1e9315974, content=<a href='/topic/show?id=515b1519009' target=_blank style='color:#2F92EE;'>#RCC患者#</a>, objectTitle=JCO：卡博替尼对比舒尼替尼作为mRCC患者初始靶向治疗的差异与风险评估(Alliance A031203 CABOSUN 试验), objectType=article, longId=82815, objectId=ec4a8281505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec4a8281505, replyNumber=0, likeNumber=39, createdTime=2016-11-26, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec4a8281505, moduleTitle=JCO：卡博替尼对比舒尼替尼作为mRCC患者初始靶向治疗的差异与风险评估(Alliance A031203 CABOSUN 试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec4a8281505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793158, encodeId=4a9e1e931582e, content=<a href='/topic/show?id=515b1519009' target=_blank style='color:#2F92EE;'>#RCC患者#</a>, objectTitle=BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期, objectType=article, longId=50059, objectId=70ba50059c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ba50059c4, replyNumber=0, likeNumber=34, createdTime=2015-09-06, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ba50059c4, moduleTitle=BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ba50059c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

RCC患者

2020-05-29

ms55066533437992 (审核中...)

前往app查看评论内容

#RCC患者#

Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？

2021-11-04

ms55066533437992 (审核中...)

前往app查看评论内容

#RCC患者#

Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效

2022-03-25

ms55066533437992 (审核中...)

前往app查看评论内容

#RCC患者#

Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果

2022-07-20

ms55066533437992 (审核中...)

前往app查看评论内容

#RCC患者#

JAMA子刊：掀起“谈痣色变”风的黑色素瘤与肾癌密不可分！46岁以下RCC患者都应该进行这些基因筛查！

2022-09-26

ms55066533437992 (审核中...)

前往app查看评论内容

#RCC患者#

Cell Death & Disease：抗雌激素药物Faslodex能够增加RCC患者对Sunitinib的敏感性

2021-04-26

ms55066533437992 (审核中...)

前往app查看评论内容

#RCC患者#

JCO：卡博替尼对比舒尼替尼作为mRCC患者初始靶向治疗的差异与风险评估(Alliance A031203 CABOSUN 试验)

2016-11-26

ms55066533437992 (审核中...)

前往app查看评论内容

#RCC患者#

BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期

2015-09-06

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#RCC患者#

科室

工具

服务